These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 5311767)

  • 21. Dose-related alterations in metabolism of levodopa: possible mechanism for hypotensive effect.
    Kochar MS; Itskovitz HD; Sasse EA; Baker JD; Doumas BT
    J Clin Pharmacol; 1974; 14(8):448-54. PubMed ID: 4851433
    [No Abstract]   [Full Text] [Related]  

  • 22. Central monoamine metabolism in Parkinson's disease.
    Chase TN; Ng LK
    Arch Neurol; 1972 Dec; 27(6):486-91. PubMed ID: 5083866
    [No Abstract]   [Full Text] [Related]  

  • 23. Catecholamine metabolism during oral administration of levodopa.
    Hinterberger H; Andrews CJ
    Arch Neurol; 1972 Mar; 26(3):245-52. PubMed ID: 5061285
    [No Abstract]   [Full Text] [Related]  

  • 24. On the relationship between L-DOPA therapy and CSF monoamine metabolites in Parkinson's disease.
    Casati C; Agnoli A; Jori A; Dolfini E
    Z Neurol; 1973 Apr; 204(2):149-54. PubMed ID: 4121468
    [No Abstract]   [Full Text] [Related]  

  • 25. Responses of the urinary excretion of homovanillic acid and of 5-hydroxy-indol-acetic acid to treatment with L-dopa and amantadine.
    Molnár G; Fodor A
    Ther Hung; 1973; 21(1):35-40. PubMed ID: 4792890
    [No Abstract]   [Full Text] [Related]  

  • 26. Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease.
    Hare TA; Vanna S; Beasley B; Chambers R; Vogel WH
    J Lab Clin Med; 1971 Feb; 77(2):319-25. PubMed ID: 5540775
    [No Abstract]   [Full Text] [Related]  

  • 27. Biochemical investigations in patients with Parkinson's disease treated with L-dopa.
    Jequier E; Dufresne JJ
    Neurology; 1972 Jan; 22(1):15-21. PubMed ID: 5061836
    [No Abstract]   [Full Text] [Related]  

  • 28. [Qualitative analysis of the main urinary metabolites of dopamine, epinephrine and norepinephrine by gas chromatography].
    Bègue RJ; Bazerolle O; Desgres J; Lallemant C; Padieu P
    Pathol Biol (Paris); 1971; 19(15):719-25. PubMed ID: 4942503
    [No Abstract]   [Full Text] [Related]  

  • 29. 5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L dopa.
    Johansson B; Roos BE
    Eur J Clin Pharmacol; 1971 Sep; 3(4):232-5. PubMed ID: 5151306
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of cannabis sativa administered by smoking on biogenic amine excretion in man.
    Messiha FS; Soskin RA
    Res Commun Chem Pathol Pharmacol; 1973 Jul; 6(1):325-8. PubMed ID: 4734006
    [No Abstract]   [Full Text] [Related]  

  • 31. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.
    Mars H
    Trans Am Neurol Assoc; 1973; 98():241-5. PubMed ID: 4784941
    [No Abstract]   [Full Text] [Related]  

  • 32. [Studies on the mechanism of action of a new cardiac beta-aminoketone. Behavior of the metabolism of biogenic amines in humans].
    Krautheim J; Schmid E
    Arzneimittelforschung; 1966 Nov; 16(11):1500-2. PubMed ID: 6014966
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of L-DOPA treatment on indole metabolism in Parkinson's disease.
    Brune GG; Pflughaupt KW
    Experientia; 1971 May; 27(5):516. PubMed ID: 5132580
    [No Abstract]   [Full Text] [Related]  

  • 34. ["Precursor-therapy" with active amines. 2. Treatment of Parkinson's disease by L-5-HTP (L-5-hydroxytryptophan)].
    Sano I; Taniguchi K
    Seishin Shinkeigaku Zasshi; 1971; 73(11):835-9. PubMed ID: 5316906
    [No Abstract]   [Full Text] [Related]  

  • 35. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
    Pullar IA; Dowson JH; Ahmed R; Chow R; Gillingham FJ
    Confin Neurol; 1972; 34(1):143-8. PubMed ID: 5084388
    [No Abstract]   [Full Text] [Related]  

  • 36. Peripheral aromatic L-amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism of L-2- 14 C-dopa.
    Bianchine JR; Messiha FS; Hsu TH
    Clin Pharmacol Ther; 1972; 13(4):584-94. PubMed ID: 5042372
    [No Abstract]   [Full Text] [Related]  

  • 37. L-Dopa, B 6 , and alpha-methyldopa hydrazine.
    Klawans HL; Ringel SP
    Confin Neurol; 1973; 35(3):186-92. PubMed ID: 4712885
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor].
    Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Zamponi A
    Minerva Med; 1972 Dec; 63(89):4853-61. PubMed ID: 4566743
    [No Abstract]   [Full Text] [Related]  

  • 39. Predictive value of the probenecid test for the effect of L-DOPA therapy in Parkinson's disease.
    Lakke JP; Korf J; Van Praag HM; Schut T
    Nat New Biol; 1972 Apr; 236(68):208-9. PubMed ID: 4553111
    [No Abstract]   [Full Text] [Related]  

  • 40. Histochemical studies on the metabolism of L-DOPA and some related substances in the exocrine pancreas.
    Alm P; Ehinger B; Falck B
    Acta Physiol Scand; 1969; 76(1):106-20. PubMed ID: 5307270
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.